Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Gilberto, de Lima Lopes"'
Autor:
Ignacio Garrido-Laguna, Asaf Maoz, Wungki Park, Abdul Rafeh Naqash, Vaia Florou, Breelyn Wilky, Jonathan Trent, Umang Swami, Garrett Frampton, Heloisa P Soares, Sonam Puri, Aik Choon Tan, Charalampos S Floudas, Carter Norton, Ethan S Sokol, Peter Hosein, Gilberto de Lima Lopes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Background Pembrolizumab is FDA approved for tumors with tumor mutational burden (TMB) of ≥10 mutations/megabase (mut/Mb). However, the response to immune checkpoint inhibitors (ICI) varies significantly among cancer histologies. We describe the la
Externí odkaz:
https://doaj.org/article/206cd2d9903d405d9e63f577bd3f9aea
Autor:
Samuel A. Kareff, Kunal Gawri, Khadeja Khan, Deukwoo Kwon, Estelamari Rodriguez, Gilberto de Lima Lopes, Richa Dawar
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Current first-line standard therapy for metastatic non-small cell lung cancer without driver mutations involves chemotherapy and immunotherapy combination. Prior to the advent of immune checkpoint inhibition, REVEL, a randomized phase III trial demon
Externí odkaz:
https://doaj.org/article/3276ac32e4964d1aab5b0cedacda126b
Autor:
Toni K. Choueiri, Chris Labaki, Ziad Bakouny, Chih-Yuan Hsu, Andrew L. Schmidt, Gilberto de Lima Lopes, Jr., Clara Hwang, Sunny R.K. Singh, Chinmay Jani, Lisa B. Weissmann, Elizabeth A. Griffiths, Susan Halabi, Ulysses Wu, Stephanie Berg, Timothy E. O'Connor, Trisha M. Wise-Draper, Orestis A. Panagiotou, Elizabeth J. Klein, Monika Joshi, Fares Yared, Miriam Santos Dutra, Na Tosha N. Gatson, Sibel Blau, Harpreet Singh, Rahul Nanchal, Rana R. McKay, Taylor K. Nonato, Ryann Quinn, Samuel M. Rubinstein, Matthew Puc, Blanche H. Mavromatis, Praveen Vikas, Bryan Faller, Howard A. Zaren, Salvatore Del Prete, Karen Russell, Daniel Y. Reuben, Melissa K. Accordino, Christopher R. Friese, Sanjay Mishra, Donna R. Rivera, Yu Shyr, Dimitrios Farmakiotis, Jeremy L. Warner
Publikováno v:
The Lancet Regional Health. Americas, Vol 19, Iss , Pp 100445- (2023)
Summary: Background: Breakthrough SARS-CoV-2 infections following vaccination against COVID-19 are of international concern. Patients with cancer have been observed to have worse outcomes associated with COVID-19 during the pandemic. We sought to eva
Externí odkaz:
https://doaj.org/article/e370428645e4460e9f6ede1b1e0c1c34
Autor:
Marcos Aurélio Fonseca Magalhães Filho, Pedro Nazareth Aguiar Jr., Milena Brachmans Mascarenhas Neves, Gilberto de Lima Lopes Jr., Auro del Giglio
Publikováno v:
Einstein (São Paulo), Vol 20 (2022)
ABSTRACT Objective Human epidermal growth factor receptor 2 (HER2) overexpression occurs in up to 30% of breast cancer cases. Ado-trastuzumab emtansine (T-DM1) is approved to treat residual HER2-positive breast cancer after neoadjuvant therapy. The a
Externí odkaz:
https://doaj.org/article/9e06eda09e8340119e5ddc732253becb
Autor:
Eva Segelov, Hans Prenen, Daphne Day, C. Raina Macintyre, Estelle Mei Jye Foo, Raghib Ali, Quanyi Wang, Xiaoting Wei, Gilberto de Lima Lopes, Kefeng Ding, Gong Chen, John Whay Kuang Chia, Han Chong Toh
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 585-588 (2020)
Externí odkaz:
https://doaj.org/article/54db7ec56ed34fa699baf42e80a421a6
Autor:
Vakaramoko Diaby, Hussain Alqhtani, Sascha van Boemmel-Wegmann, Ching-Yu Wang, Askal Ayalew Ali, Rajesh Balkrishnan, Yu Ko, Sofia Palacio, Gilberto de Lima Lopes
Publikováno v:
Breast, Vol 49, Iss , Pp 141-148 (2020)
Objective: Treatment options for HER-2-positive metastatic breast cancer (mBC) patients have expanded markedly since trastuzumab approval in 1998. Several other regimens are now available, including pertuzumab plus trastuzumab plus docetaxel, T-DM1,
Externí odkaz:
https://doaj.org/article/df8edb39d6df48dbb6099fdfb6e5ee97
Autor:
Carlos Barrios, Gilberto de Lima Lopes, Mastura Md Yusof, Fidel Rubagumya, Piotr Rutkowski, Manju Sengar
Publikováno v:
Nature Reviews Clinical Oncology. 20:7-15
Autor:
Vakaramoko Diaby, Ching-Yu Wang, Hussain Alqhtani, Sascha van Boemmel-Wegmann, Askal Ayalew Ali, Rajesh Balkrishnan, Yu Ko, Sofia Palacio, Gilberto de Lima Lopes
Publikováno v:
Data in Brief, Vol 29, Iss , Pp - (2020)
The present data article aims to describe the input parameters for a Markov model assessing the cost-effectiveness of four treatment sequences for patients with HER-2 positive metastatic breast cancer. The model input parameters include costs for phy
Externí odkaz:
https://doaj.org/article/90b82485620842c5b2ce5504252cdcdf
Autor:
Dame Idossa, Ana I. Velazquez, Miki Horiguchi, Julia Alberth, Inas Abuali, Demetria Smith-Graziani, Gilberto de Lima Lopes, Sam Lubner, Narjust Florez
Publikováno v:
JCO Oncology Practice.
PURPOSE Physician workforce diversity can be a driver of institutional excellence, improving innovation and reducing health disparities. However, the current diversity of the hematology/oncology (HO) workforce does not reflect that of the US populati
Autor:
Roselle De Guzman, Monica Malik, Gilberto de Lima Lopes Jr, Rebecca Alexandra Dent, Shaheenah Dawood
Publikováno v:
Journal of Global Oncology, Vol 4, Pp 1-3 (2018)
Externí odkaz:
https://doaj.org/article/d9870960ecff42deaa433bc7db655fe2